רופילק 300

Country: ইস্রায়েল

ভাষা: হিব্রু

সূত্র: Ministry of Health

সক্রিয় উপাদান:

ANTI-D IMMUNOGLOBULINS

থেকে পাওয়া:

CSL BEHRING LTD., ISRAEL

এটিসি কোড:

J06BB01

ফার্মাসিউটিকাল ফর্ম:

תמיסה להזרקה

রচনা:

ANTI-D IMMUNOGLOBULINS 150 MCG/ML

প্রশাসন রুট:

תוך-שרירי, תוך-ורידי

প্রেসক্রিপশন টাইপ:

מרשם נדרש

Manufactured by:

CSL BEHRING AG, SWITZERLAND

Therapeutic group:

ANTI-D (RH) IMMUNOGLOBULIN

Therapeutic area:

ANTI-D (RH) IMMUNOGLOBULIN

থেরাপিউটিক ইঙ্গিত:

Prophylaxis of Rh (D) immunisation in Rh (D)-negative women: Anti-D immune globulin is administered for the prevention of Rh (D) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. Treatment is not necessary when it is assured that the child or the father are Rh (D)- negative. Criteria for a rhesus-incompatible pregnancy and the administration of anti-D immune globulin are : a) the mother is Rh (D) -negative b) the child is either Rh (D)-positive Rh (D)weak - positive or its rhesus type is not known. Routine antepartum prophylaxis : To prevent Rh (D) immunisation due to spontaneous fetomaternal haemorrhage (FMH) during the last trimester of pregnancy. Postpartum prophylaxis To prevent Rh (D) immunisation of the Rh (D)-negative mother following delivery of a Rh (D)-positive child. Complications of pregnancy: Interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

অনুমোদন তারিখ:

2023-02-28